111 related articles for article (PubMed ID: 12211423)
1. Atrasentan Abbott.
Norman P
Curr Opin Investig Drugs; 2002 Aug; 3(8):1240-8. PubMed ID: 12211423
[TBL] [Abstract][Full Text] [Related]
2. Atrasentan demonstrates survival benefit in hormone-refractory prostate cancer.
Expert Rev Anticancer Ther; 2002 Jun; 2(3):245. PubMed ID: 12113043
[No Abstract] [Full Text] [Related]
3. The endothelin axis: emerging role in cancer.
Nelson J; Bagnato A; Battistini B; Nisen P
Nat Rev Cancer; 2003 Feb; 3(2):110-6. PubMed ID: 12563310
[TBL] [Abstract][Full Text] [Related]
4. Zibotentan for the treatment of castrate-resistant prostate cancer.
Shepard DR; Dreicer R
Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
[TBL] [Abstract][Full Text] [Related]
5. Atrasentan for metastatic hormone refractory prostate cancer.
Murphy G
Issues Emerg Health Technol; 2005 Dec; (77):1-4. PubMed ID: 16544441
[TBL] [Abstract][Full Text] [Related]
6. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
Zonnenberg BA; Groenewegen G; Janus TJ; Leahy TW; Humerickhouse RA; Isaacson JD; Carr RA; Voest E
Clin Cancer Res; 2003 Aug; 9(8):2965-72. PubMed ID: 12912943
[TBL] [Abstract][Full Text] [Related]
7. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
Carducci MA; Jimeno A
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
[TBL] [Abstract][Full Text] [Related]
8. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
Nelson JB; Nabulsi AA; Vogelzang NJ; Breul J; Zonnenberg BA; Daliani DD; Schulman CC; Carducci MA
J Urol; 2003 Mar; 169(3):1143-9. PubMed ID: 12576870
[TBL] [Abstract][Full Text] [Related]
9. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
Ryan CW; Vogelzang NJ; Vokes EE; Kindler HL; Undevia SD; Humerickhouse R; André AK; Wang Q; Carr RA; Ratain MJ
Clin Cancer Res; 2004 Jul; 10(13):4406-11. PubMed ID: 15240529
[TBL] [Abstract][Full Text] [Related]
10. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.
Thakkar SG; Choueiri TK; Garcia JA
Curr Oncol Rep; 2006 Mar; 8(2):108-13. PubMed ID: 16507220
[TBL] [Abstract][Full Text] [Related]
11. Anti-endothelin drugs in solid tumors.
Russo A; Bronte G; Rizzo S; Fanale D; Di Gaudio F; Gebbia N; Bazan V
Expert Opin Emerg Drugs; 2010 Mar; 15(1):27-40. PubMed ID: 20102289
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade.
Bagnato A; Cirilli A; Salani D; Simeone P; Muller A; Nicotra MR; Natali PG; Venuti A
Cancer Res; 2002 Nov; 62(22):6381-4. PubMed ID: 12438219
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
[TBL] [Abstract][Full Text] [Related]
15. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
Carducci MA; Padley RJ; Breul J; Vogelzang NJ; Zonnenberg BA; Daliani DD; Schulman CC; Nabulsi AA; Humerickhouse RA; Weinberg MA; Schmitt JL; Nelson JB
J Clin Oncol; 2003 Feb; 21(4):679-89. PubMed ID: 12586806
[TBL] [Abstract][Full Text] [Related]
16. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054.
Growcott JW
Anticancer Drugs; 2009 Feb; 20(2):83-8. PubMed ID: 19065106
[TBL] [Abstract][Full Text] [Related]
17. Endothelin receptor antagonism and cancer.
Bhalla A; Haque S; Taylor I; Winslet M; Loizidou M
Eur J Clin Invest; 2009 Jun; 39 Suppl 2():74-7. PubMed ID: 19335749
[TBL] [Abstract][Full Text] [Related]
18. Effect of castration on endothelin receptors.
Padley RJ; Dixon DB; Wu-Wong JR
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():442S-445S. PubMed ID: 12193141
[TBL] [Abstract][Full Text] [Related]
19. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?
Cella D; Petrylak DP; Fishman M; Teigland C; Young J; Mulani P
Eur Urol; 2006 May; 49(5):781-9. PubMed ID: 16458417
[TBL] [Abstract][Full Text] [Related]
20. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.
Jimeno A; Carducci M
Expert Rev Anticancer Ther; 2005 Jun; 5(3):419-27. PubMed ID: 16001950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
